EMD Serono Unveils New MAVENCLAD ® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity

Moderated by Tomas Kauer Moderated by Tomas Kauer
Sep 12, 2024 - 16:00
EMD Serono Unveils New MAVENCLAD ® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity
Read More